Pancreatic Cancer Clinical Trials in Boston

Showing 1-20 of 117 trials

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Colorectal CancerPancreatic CancerNon-Small Cell Lung Cancer+1 more

PAQ Therapeutics, Inc.195 participantsStarted Nov 2025

Boston, Massachusetts, United States • San Antonio, Texas, United States • San Antonio, Texas, United States +2 more locations

Active Not RecruitingPhase 3< 1 mile

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma

Revolution Medicines, Inc.500 participantsStarted Oct 2024

Gilbert, Arizona, United States • Phoenix, Arizona, United States • Duarte, California, United States +57 more locations

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Cancer Trials in Other Cities

Resilience and Equity in Aging, Cancer, and Health (REACH)

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury

Video Education With Result Dependent dIsclosure

Switch Maintenance in Pancreatic

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

A Study of MGC026 in Participants With Advanced Solid Tumors

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Other Conditions in Boston